Mallinckrodt Signs its First RNAi Deal with Silence Therapeutics

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 8 (Table of Contents)

Published: 1 Aug-2019

DOI: 10.3833/pdr.v2019.i8.2444     ISSN: 1756-7874

Section: Licensing



Joining the likes of Janssen, Eli Lilly and Regeneron, Mallinckrodt has now ventured into the field of RNAi therapeutics with a potential US$2...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details